background: intravenous immunoglobulin (ivig) is an established treatment of immune mediated demyelinating neuropathy including guillain-barré syndrome and chronic inflammatory demyelinating polyneuropathy. recent trials suggest its efficacy in treating relapsing- remitting multiple sclerosis. ivig exerts a number of effects, which may be beneficial in treating multiple sclerosis (ms): reductio...

It is uncertain as to whether similar or different mechanisms contribute to different subtypes of multiple sclerosis (MS). A unifying concept proposes that patients with both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS) have premature thymic involution, which alters peripheral T-cell homeostasis and leads to T-cell alterations that contribute to the pathogenesis of both MS su...

OBJECTIVE Neuromyelitis optica and its spectrum disorder (NMOSD) can present similarly to relapsing-remitting multiple sclerosis (RRMS). Using a quantitative lesion mapping approach, this research aimed to identify differences in MRI brain lesion distribution between aquaporin-4 antibody-positive NMOSD and RRMS, and to test their diagnostic potential. METHODS Clinical brain MRI sequences for ...

We report a patient with relapsing-remitting multiple sclerosis (RRMS), who developed bilateral severe tongue weakness due to the anterior opercular syndrome. This was caused by a recent inflammatory demyelinating lesion in the right perisylvian juxtacortical region, superimposed on a pre-existing left perisylvian lesion, which had previously caused temporary isolated right tongue weakness.

Multiple sclerosis (MS) is the most prevalent immune-mediated inflammatory demyelinating central nervous system disorder, with a diverse set of clinical signs and symptoms. This study aimed to investigate diagnostic values monocyte/lymphocyte ratio (MLR), red cell distribution width/lymphocyte (RLR), systemic immune-inflammation index (SII) in detecting multiple attacks patients Relapsing-remit...

Raphael Schneider, MD Nathalie Arbour, PhD The topic of this Journal Club is a study by Bielekova et al.,1 who assessed whether daclizumab monotherapy reduces contrast-enhancing lesions (CEL) in patients with relapsing-remitting multiple sclerosis (RRMS). Furthermore, they evaluated the effects of daclizumab on clinical outcome measures and on NK cell populations in the CSF and blood of treated...

Raphael Schneider, MD Nathalie Arbour, PhD The topic of this Journal Club is a study by Bielekova et al.,1 who assessed whether daclizumab monotherapy reduces contrast-enhancing lesions (CEL) in patients with relapsing-remitting multiple sclerosis (RRMS). Furthermore, they evaluated the effects of daclizumab on clinical outcome measures and on NK cell populations in the CSF and blood of treated...

BACKGROUND Multiple sclerosis (MS) is a highly prevalent cause of neurological disability and has different clinical subtypes with potentially different underlying pathologies. Differentiation of primary progressive multiple sclerosis (PPMS) from relapsing remitting multiple sclerosis (RRMS) could be difficult especially in its early phases. OBJECTIVES We compared brain metabolite concentrati...

soluble forms of nonclassical human leukocyte antigen (hla)-g have recently been suggested as immunomodulatory factors in multiple sclerosis (ms). hla-g inhibits the effecter function of t cells and natural killer (nk) cells. also regulatory t cells (treg) are considered as pivotal players in ms pathogenesis. thus, we aimed to evaluate the presence of hla-g molecules and treg cells in relapsing...

OBJECTIVE The aim of this study was to characterize the microscopic damage to the corpus callosum in relapsing-remitting multiple sclerosis (RRMS) with diffusion tensor imaging and to investigate the correlation of this damage with disability. The diffusion tensor imaging parameters of fractional anisotropy and mean diffusivity provide information about the integrity of cell membranes, offering...